High-dose chemotherapeutic approaches to ovarian cancer management

Seminars in Oncology

Volumn 27, Issue 3 SUPPL. 7, 2000, Pages 41-46

  McGuire III, W P ^a  

^a MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ADULT; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0033899386     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Cancer statistics, 2000
2. Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer
3. High-dose chemotherapy in ovarian carcinoma
4. High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for tumors
5. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma
6. Treatment of advanced epithelial ovarian cancer using cisplatin, Adriamycin and Cytoxan - The Indiana University experience
7. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer
8. Cisplatin dose-intensity in advanced ovarian cancer: A randomized study of conventional dose-intense cisplatin monochemotherapy
9. Mature results of a prospective randomized trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma
10. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study
11. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer
12. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest
13. A randomized study of high versus standard dose carboplatin in patients (pts) with advanced epithelial ovarian cancer (EOC)
14. Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study
15. Prospective randomized trial of cisplatin/carboplatin versus conventional cisplatin/cyclophosphamide in epithelial ovarian cancer: First results of the impact of platinum dose intensity on patient outcome
16. How many more nails to seal the coffin of dose intensity?
17. Dose-intensity in ovarian carcinoma: Hold, enough?
18. Intraperitoneal therapy of ovarian cancer
19. Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group study
20. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin
21. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
22. Randomized phase III study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): An Intergroup trial (GOG, SWOG, ECOG)
23. Intraperitoneal treatment and dose-intense therapy in ovarian cancer
24. Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support
25. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma
26. Multiple cycles of high-dose chemotherapy for ovarian cancer
27. Outcome of autotransplants for advanced ovarian cancer
28. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCCTG and ECOG study